PUBLISHER: The Business Research Company | PRODUCT CODE: 1662352
PUBLISHER: The Business Research Company | PRODUCT CODE: 1662352
Sexually Transmitted Diseases (STDs) diagnostics encompass the examination and identification of infectious conditions transmitted through sexual contact. These diagnostic procedures are essential in determining the presence of STDs within an individual.
The primary categories of STD diagnostics include chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus, human immunodeficiency virus, chancroid, and other tests performed in laboratory and point-of-care settings. Chlamydia testing involves a urine sample analysis to detect infection. This specific test is employed for identifying chlamydia infections, a common bacterial sexually transmitted infection (STI) transmitted through various forms of sexual contact or genital exposure. These STD diagnostic procedures find application in hospitals, clinics, diagnostic centers, and homecare settings.
The STD diagnostics market research report is one of a series of new reports from The Business Research Company that provides STD diagnostics market statistics, including STD diagnostics industry global market size, regional shares, competitors with a STD diagnostics market share, detailed STD diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the STD diagnostics industry. This STD diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The STD diagnostics market size has grown strongly in recent years. It will grow from $9.93 billion in 2024 to $10.86 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to epidemiological trends, healthcare infrastructure development, pharmaceutical developments, sexual education programs, demographic shifts.
The STD diagnostics market size is expected to see rapid growth in the next few years. It will grow to $16.21 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to personalized medicine trends, healthcare access improvements, population health strategies, telemedicine and digital health, rising incidence of STDs. Major trends in the forecast period include point-of-care testing (POCT) advancements, home testing kits, multiplex testing, targeted marketing and outreach, pre-exposure prophylaxis (prep) programs, rising incidence rates.
The escalating prevalence of sexually transmitted diseases (STDs) is a significant driver propelling the STD diagnostics market forward. STDs, infectious diseases transmitted through sexual contact, have become a global health concern. In 2022, the World Health Organization reported that over 1 million sexually transmitted infections are acquired daily worldwide, with approximately 374 million new infections annually, including chlamydia, gonorrhea, syphilis, and trichomoniasis. The rising incidence of STDs underscores the critical role of STD diagnostics in efficient analysis and testing, driving the market's growth.
The increasing healthcare expenditure is anticipated to drive the growth of the STD diagnostics market in the future. Healthcare expenditure refers to the overall amount of money spent on healthcare services, related goods, and activities within a specific healthcare system or economy over a defined period. This expenditure is relevant to STD diagnostics as it signifies a strategic investment in preventive healthcare, addresses public health priorities, and contributes to overall health and well-being at both individual and community levels. For example, in May 2024, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, marking a significant increase compared to the 0.9% growth recorded in 2022. Thus, the rise in healthcare expenditures is fueling the growth of the STD diagnostics market.
The advancement of STD diagnostics is a significant trend within the STD diagnostic market. Major players are enhancing testing facilities and techniques to facilitate quicker and more accurate diagnoses of sexually transmitted diseases. For example, in May 2022, BD (Becton, Dickinson, and Company), a US-based medical technology firm, launched a fully automated, high-throughput molecular diagnostics platform for infectious diseases called the BD CORTM MX/PX System. This platform integrates and automates the molecular laboratory workflow, from sample processing to the delivery of diagnostic test results. The first test available on this new platform is the BD CTGCTV2 molecular assay, which is a single test capable of identifying the three most prevalent non-viral STIs (sexually transmitted infections): Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV).
Key companies in the STD diagnostics market are focusing on developing innovative products, such as real-time PCR kits, to meet unmet medical needs and improve diagnostic capabilities. A real-time PCR kit consists of a collection of reagents utilized for conducting real-time polymerase chain reaction (qPCR), a sensitive and commonly employed technique for detecting and quantifying specific nucleic acid sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based research and development company, introduced the Mycoplasma Hominis Real Time PCR Kit and the Treponema Pallidum Real Time PCR Kit, specifically designed for detecting Mycoplasma hominis and Treponema pallidum. These kits offer high sensitivity and specificity, user-friendliness, rapid turnaround times, and the capability to detect multiple pathogens in a single test.
In February 2024, Thyrocare, an India-based healthcare company, acquired Think Health Care for an undisclosed amount. With this acquisition, Thyrocare aims to strategically enhance its service offerings and market reach, especially in the home healthcare segment. Think Health Care is an India-based company specializing in diagnostic and preventive healthcare, known for providing at-home ECG services.
Major companies operating in the STD diagnostics market are Siemens AG, Abbott Laboratories, Qiagen Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Bio-Rad Laboratories Inc., Becton Dickinson and Company, Thermo Fisher Scientific Inc., Biocartis NV, Trinity Biotech PLC, Binx Health Inc., NOWDiagnostics Inc., Atlas Genetics Ltd., BioFire Diagnostics LLC, BioMerieux SA, Chembio Diagnostic Systems Inc., Corgenix Medical Corporation, Creative Diagnostics, Curetis AG, Daktari Diagnostics, Enzo Biochem Inc., Fujirebio Diagnostics Inc., GenePOC Inc., GenMark Diagnostics Inc., Grifols Diagnostic Solutions Inc., Hain Lifescience GmbH, InDevR Inc., Karius Inc., Luminex Corporation, Meridian Bioscience Inc., Mesa Biotech Inc., Mobidiag Oy
North America was the largest region in the STD diagnostics market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the std diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the std diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The STD diagnostics market consists of revenues earned by entities by providing STD diagnostics tests such as cultural/isolated tests of organisms, molecular tests, and immunology assays. The market value includes the value of related goods sold by the service provider or included within the service offering. The STD diagnostics market also includes sales of thermal cyclers, PCR, lateral flow readers - immuno chromatographic assays, flow cytometers, differential light scattering machines, absorbance microplate readers, phone chips, and rapid diagnostic kits which are used in providing STD diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
STD Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on std diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for std diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The std diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.